Biocon Limited
Working at Biocon Limited
Company Summary
Overall Rating

On-Par with

Highly rated for
Job security, Work-life balance

Critically rated for
Promotions
Work Policy




Top Employees Benefits
About Biocon Limited
We are a global biopharmaceutical company which believes that everyone has a right to affordable quality medicines.
Powered by advanced therapy platforms, our 13,500+ employees blend heart, science and creativity to make better healthcare solutions.
Our 4 global businesses include generics, biosimilars, research services and novel biologics. They represent Biocon’s risk-balanced strategy, underpinned by agile network connections, a robust pipeline and a timely ‘emerging markets’ orientation.
We have leveraged India’s value advantage of unmatched scientific talent and cost-competitive manufacturing to deliver scale, speed and quality. By making medicines more easily accessible for patients across the globe, we’re working towards achieving health equity.
We are committed to providing everyone, everywhere, affordable access to a speciality portfolio of medicines.
We are steadfastly investing in developing novel therapies for diabetes, oncology and immunology. We are strengthening our global reach and economies of scale.
Biocon Research
Biocon Foundation
Biocon Limited Ratings
Overall Rating
Category Ratings
Job security
Work-life balance
Company culture
Skill development
Salary
Work satisfaction
Promotions
Work Policy at Biocon Limited
Biocon Limited Reviews
Top mentions in Biocon Limited Reviews
Compare Biocon Limited with Similar Companies
Change Company | Change Company | Change Company | ||
---|---|---|---|---|
Overall Rating | 3.9/5 based on 1.9k reviews | 4.0/5 based on 5.8k reviews | 4.1/5 based on 6.9k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Work-life balance Job security | Salary Skill development Job security | Skill development Salary Work-life balance | Skill development Work-life balance Salary |
Critically Rated for | Promotions | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 83% employees reported | Work from office 82% employees reported | Work from office 73% employees reported | - |
Rating by Women Employees | 3.9 Good rated by 281 women | 4.0 Good rated by 437 women | 4.1 Good rated by 682 women | - no rating available |
Rating by Men Employees | 3.9 Good rated by 1.5k men | 4.0 Good rated by 5k men | 4.1 Good rated by 5.8k men | - no rating available |
Job security | 3.8 Good | 3.8 Good | 3.7 Good | 4.0 Good |
Biocon Limited Salaries
Junior Executive
Deputy Manager
Executive Production
Senior Scientist
Principal Scientist
Executive Engineer
Scientist
Territory Business Manager
QC Executive
Associate Director
Biocon Limited Interview Questions
Interview questions by designation
Top Biocon Limited interview questions and answers
Biocon Limited Jobs
Biocon Limited News
Stock Market Today: All You Need To Know Going Into Trade On Feb. 25
- Indian benchmark indices closed lower on Monday, with Nifty at 22,553.35 and Sensex at 74,454.41, marking their longest losing streak since November 1996.
- Foreign portfolio investors sold Indian equities worth Rs 6,286.7 crore while domestic institutional investors bought equities worth Rs 5,185.7 crore.
- The Indian rupee ended flat at 86.71 per dollar after erasing early gains, following a slump in US business activity.
- Stocks to watch include ONGC, NTPC, Firstsource Solutions, and Biocon, among others, with updates on their investments and developments.
- Trading tweaks included price band changes, stocks trading ex-dividend, and movements in the ASM framework for various companies.
- In F&O cues, Nifty futures were down, open interest decreased, and key levels for Options Feb. 27 Expiry were at 23,000 and 22,500.
- Bulk deals saw Quality Power Electrical Equipments and Pentateam Inventure Capital involved in significant share transactions.
- Insider trades included acquisitions by promoters in NCL Industries, Alembic Pharma, and KCP, among others.
- Scheduled meetings between companies and investors/analysts for Fino Payments Bank, Axis Bank, and others were announced.
- The Indian rupee finished flat against the US dollar at 86.71, witnessing pressure due to weakening US business activity.

Biocon Board Okays Issuing Of Commercial Papers Worth Rs 570 Crore
- Biocon Ltd. plans to raise Rs 570 crore through the issuance of commercial papers on a private placement basis.
- Commercial papers are short-term, unsecured debt obligations issued as an alternative to costlier funding methods.
- Biocon has also achieved an improvement in its Environmental, Social, and Governance (ESG) scores, with an S&P Global ESG score of 69 in 2024.
- This places Biocon in the 98th percentile among its global biotechnology industry peers.

"Tragic to See This Happen,” Biocon Chief Regrets as Fire at Bengaluru’s Startup Hub Causes Loss of Rs 150 Cr
- A massive fire at the Bangalore Bioinnovation Centre (BBC) in Electronics City caused a loss of around Rs 150 crore.
- Karnataka IT-BT minister Priyank Kharge expressed commitment to helping affected startups rebuild.
- Biocon Limited Executive Chairperson Kiran Mazumdar-Shaw expressed regret and emphasized the need for fire preparedness.
- Startups at the BBC have incurred losses ranging from Rs 80 crore to Rs 110 crore, with damage to BBC properties around Rs 42 crore.

F&O Query: Should you hold Biocon put option?
- Biocon stock has been moving in a sideways trend since July last year, with a resistance at ₹385-₹395.
- The stock is currently trading near the upper end of the range and could see a drop to ₹325, with support at ₹350.
- Holding the 320-put option is recommended as the stock may decline soon, but a drop below ₹320 is less likely.
- If the stock declines to ₹350-₹335 in about a week, the 320-put option's premium could rise to ₹1-₹3 with a target of ₹2.

The Fifth Episode of Crafting Bharat: Deep Tech with Fermbox Bio
- India's bioeconomy has witnessed a surge from US$10 billion in 2014 to over US$130 billion in 2024.
- Fermbox Bio is pioneering precision fermentation as India's tech ecosystem flourishes.
- Fermbox Bio is building a million-litre fermentation facility in Thailand in partnership with BBGI.
- Fermbox Bio's goal is to disrupt global fermentation by focusing on collaboration and scalability.
- Nithish Kumar from Speciale Invest interviews Fermbox Bio's Subramani Ramachandrappa in this episode.
- They discuss the complexities of the biotech sector and what precision fermentation means.
- Fermbox Bio makes enzymes free of animal derivatives to make vaccines safer.
- Subramani Ramachandrappa left Biocon to start his entrepreneurial journey with Richcore.
- Richcore was later acquired by Laurus Labs, paving the way for the establishment of Fermbox Bio.
- Subramani Ramachandrappa believes biotech's future will lie in openness and partnerships.

Stock Market Live Updates 3 January 2025: Stock to buy today: Mahindra & Mahindra (₹3,210) BUY
- Benchmark indices rose over 1.8 per cent on Thursday, led by strong buying in index heavyweights.
- The Sensex settled at 79,943, up 1,436 points or 1.83 per cent from its previous close.
- The Nifty50 ended at 24,188, up 445 points or 1.88 per cent.
- Smallcap 100 Index posted a more modest gain of 0.64 per cent.
- Strong buying was seen in heavyweights especially auto, NBFCs and IT stocks, driven by optimism about upcoming quarterly earnings.
- DMart added 10 stores during the quarter, taking the count to 387 stores.
- Shaily Innovations FZCO, in Dubai, UAE, will be engaged in contracts involving design and development of drug delivery devices.
- NHPC received Rs 250 crore as the second installment of gross payment under a mega insurance policy.
- Biocon receives NMPA approval for Tacrolimus capsules in China.
- Deepak Builders saw CRISIL upgrading the company's long term rating to BBB+.

Stocks that will see action today: January 3
- SEBI dismisses settlement applications filed by Zee Entertainment and Punit Goenka, referring the matter for further investigation.
- Biocon Pharma receives approval for Tacrolimus capsule from the NMPA, China.
- NHPC receives a payment of ₹250 crore under a mega insurance policy for loss caused by a flash flood.
- V2 Retail reports a 58.1% increase in revenue from operations for the December quarter.

Biocon Sells Syngene’s Shares Worth Rs 686 Crore
- Biocon Ltd. sold Syngene shares worth Rs 686 crore via block deals on the BSE, reducing its stake while maintaining majority ownership at 52.46%.
- The transaction took place in the open market and none of the buyers belong to the promoter, promoter group, or group companies.
- Biocon's subsidiary Biocon Biologics Ltd. received US FDA approval for Yesintek, a biosimilar for Johnson & Johnson's reference product, Stelara.
- For the second quarter of fiscal 2025, Biocon's consolidated net profit fell 84.3% to Rs 27.1 crore compared to the year-ago period.

AdvantageClub.ai bags $4M in funding led by Axilor Ventures
- AdvantageClub.ai, a company specializing in employee engagement solutions, has raised $4 million in a funding round led by Axilor Ventures.
- The funding round also saw participation from AFG Ventures, Prasanna Sarkar, Bytez Ventures, and existing ventures, bringing the total funding raised by AdvantageClub.ai to $11 million.
- The company plans to utilize the funding to expand into the US and Asia, strengthen its position in rewards and recognition, and develop wellness programs.
- AdvantageClub.ai, founded in 2016, provides its services to clients such as Tech Mahindra, HCL, Concentrix, Hexaware, Biocon, Tata Steel, and Air India.

Biocon Biologics Receives US FDA Nod For Yesintek, A Biosimilar to J&J's Stelara
- Biocon Biologics has received FDA approval for Yesintek, a biosimilar for Johnson & Johnson's Stelara.
- Yesintek, a monoclonal antibody, will treat Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
- This approval will provide affordable access to high-quality biosimilars for millions of patients worldwide.
- Biocon Biologics is set to commercialize Yesintek in the United States by February 22, 2025.
Biocon Limited Offices
Compare Biocon Limited with




















Contribute & help others!
Companies Similar to Biocon Limited












Biocon Limited FAQs
Reviews
Interviews
Salaries
Users/Month